Myokardia Inc (NASDAQ:MYOK) Shorted Shares Increased 10.52% After Market Selling

March 22, 2018 - By Linda Rogers

 Myokardia Inc (NASDAQ:MYOK) Shorted Shares Increased 10.52% After Market Selling

The stock of Myokardia Inc (NASDAQ:MYOK) registered an increase of 10.52% in short interest. MYOK’s total short interest was 1.71 million shares in March as published by FINRA. Its up 10.52% from 1.55M shares, reported previously. With 440,900 shares average volume, it will take short sellers 4 days to cover their MYOK’s short positions. The short interest to Myokardia Inc’s float is 5.88%.

The stock increased 1.25% or $0.65 during the last trading session, reaching $52.85. About 44,010 shares traded. MyoKardia, Inc. (NASDAQ:MYOK) has risen 11.16% since March 22, 2017 and is uptrending. It has underperformed by 5.54% the S&P500.

MyoKardia, Inc., a clinical stage biopharmaceutical company, engages in discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. The company has market cap of $1.90 billion. The Company’s lead product candidate is MYK-461, an orally-administered small molecule that is in Phase II clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy . It currently has negative earnings. The firm also develops MYK-491, an orally-administered small molecule that treats genetic dilated cardiomyopathy (DCM) by restoring normal contractility in the diseased DCM heart.

MyoKardia, Inc. (NASDAQ:MYOK) Ratings Coverage

Among 5 analysts covering MyoKardia (NASDAQ:MYOK), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. MyoKardia had 5 analyst reports since November 23, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Monday, November 23 by Wedbush. The firm has “Outperform” rating given on Monday, November 23 by Cowen & Co. The stock of MyoKardia, Inc. (NASDAQ:MYOK) has “Outperform” rating given on Wednesday, July 20 by BMO Capital Markets. The rating was initiated by Credit Suisse on Monday, November 23 with “Outperform”. Wells Fargo initiated the stock with “Outperform” rating in Friday, December 4 report.

Another recent and important MyoKardia, Inc. (NASDAQ:MYOK) news was published by which published an article titled: “MyoKardia Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER …” on March 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.